# Sequential BCR::ABL1 evaluation during dose de-escalation in peripheral blood is more predictive of TFR success than single assessment at dose de-escalation in either peripheral blood or bone marrow

**Authors:** S. D. Patterson, A. Gottschalk, C. Hayden, R. Young, A. Hair, H. G. Jørgensen, H. W. Wheadon, J. F. Apperley, I. Glauche, R. E. Clark, M. Copland, I. Roeder

PMC · DOI: 10.1038/s41375-025-02853-7 · Leukemia · 2026-01-07

## Full-text entities

- **Diseases:** Blood Cancer (MESH:D019337), CML (MESH:D015464), CP-CML (MESH:D015466), Cancer (MESH:D009369)
- **Chemicals:** nilotinib (MESH:C498826), dasatinib (MESH:D000069439), tyrosine (MESH:D014443), TFR (-), imatinib (MESH:D000068877)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12875873/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12875873/full.md

---
Source: https://tomesphere.com/paper/PMC12875873